CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of diffuse large B-cell lymphoma.
  
  LEARNING OBJECTIVES

  • Apply available clinical research findings in the formation of evidence-based therapeutic approaches for patients with relapsed/refractory (R/R) DLBCL both fit and unfit for intensive therapy.
  • Evaluate the mechanisms of action of and available clinical trial findings with various CD19-directed therapies approved for R/R DLBCL, and assess the spectrum and frequency of associated toxicities.
  • Appraise the biological rationale for, recently presented research findings with and the potential clinical role of CD30-targeted antibody-drug conjugate-based therapy for R/R DLBCL.
  • Consider published research data with and the current clinical role of CD20 x CD3 bispecific antibodies for R/R DLBCL.
  • Identify patients with R/R DLBCL for whom treatment with chimeric antigen receptor T-cell therapy would be appropriate.
  • Counsel appropriate patients regarding the potential benefits of participation in ongoing clinical studies evaluating novel agents and strategies for R/R DLBCL.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Interview: Research To Practice designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Interview: Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 3.25 (audio) and 2.75 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/DLBCLThinkTank2024/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/DLBCLThinkTank2024/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/DLBCLThinkTank2024/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/DLBCLThinkTank2024.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Martin Hutchings, MD, PhD
  Senior Consultant
  Department of Haematology and Phase 1 Unit
  Rigshospitalet, Copenhagen University Hospital
  Professor of Clinical Lymphoma Research
  Department of Clinical Medicine, University of Copenhagen
  Copenhagen, Denmark
  
  Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genmab US Inc, Janssen Biotech Inc, Merck, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Genmab US Inc, Roche Laboratories Inc.
  
  Manali Kamdar, MD, MBBS
  Associate Professor
  Clinical Director of Lymphoma Services
  Morton and Sandra Saffer Endowed Chair in Hematology Research
  Division of Hematology, Hematologic Malignancies
  University of Colorado Cancer Center
  Aurora, Colorado
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group; Contracted Research: Novartis; Data and Safety Monitoring Boards/Committees: Celgene Corporation, Genentech, a member of the Roche Group.
  
  Matthew Lunning, DO
  Associate Professor of Medicine
  Medical Director, Cellular Therapy
  Associate Vice Chair of Research
  Assistant Vice Chancellor for Clinical Research
  Division of Hematology/Oncology
  Department of Internal Medicine
  University of Nebraska Medical Center
  Omaha, Nebraska
  
  Consulting/Honoraria: AbbVie Inc, Acrotech Biopharma, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Caribou Biosciences Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc, Pfizer Inc, Recordati, Regeneron Pharmaceuticals Inc, Seagen Inc, Veeva, Vittoria Biotherapeutics; Research Funding: AbbVie Inc,Bristol Myers Squibb, Fate Therapeutics, Kite, A Gilead Company.
  
  Gilles Salles, MD, PhD
  Service Chief, Lymphoma Service
  Steven Greenberg Chair
  Memorial Sloan Kettering Cancer Center
  Weill Cornell Medical College
  New York, New York
  
  Advisory Committees: AbbVie Inc, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Nurix Therapeutics Inc, Pfizer Inc; Consulting Agreements: AbbVie Inc, ATB Therapeutics, BeiGene Ltd, Bristol Myers Squibb, Debiopharm, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Kite, A Gilead Company, ModeX Therapeutics, Molecular Partners, Orna Therapeutics, Treeline Biosciences; Contracted Research: AbbVie Inc, Genentech, a member of the Roche Group, Genmab US Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Nurix Therapeutics Inc.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, and Incyte Corporation.
  
  Release date: February 2025
  Expiration date: February 2026
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.